QT Imaging Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a QTI research report →
Range $8 – $8
Price Chart
About the company
QT Imaging Holdings, Inc. is dedicated to the research, development, and manufacturing of advanced automated systems for breast imaging. These innovative devices are engineered to generate high-resolution ultrasound images utilizing transmission technology.
- CEO
- Raluca Dinu
- IPO
- 2024
- Employees
- 32
- HQ
- Novato, CA, US
Get TickerSpark's AI analysis on QTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $28.21M
- P/E
- -1.67
- Fwd P/E
- 8.53
- PEG
- -0.03
- P/S
- 0.88
- P/B
- 11.22
- EV/EBITDA
- -3.28
- Div Yield
- 0.00%
- Gross Margin
- 39.50%
- Op Margin
- -18.24%
- Net Margin
- -45.15%
- ROE
- -373.66%
- ROIC
- -27.32%
Latest fiscal year · YoY change
- Revenue
- $18.93M+287.9%
- Gross Profit
- $8.58M+225.2%
- Op Income
- $-4,437,000
- Net Income
- $-21,083,000-134.6%
- EPS
- $-2.01+5.6%
- OCF Growth
- +10.7%
- FCF Growth
- +10.3%
- 52W High
- $7.60
- 52W Low
- $1.62
- 50D MA
- $2.35
- 200D MA
- $4.21
- Beta
- -0.01
- RSI (14)
- 40
- Avg Volume
- 39.62K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
QT Imaging posted strong Q3 revenue growth and scanner sales, while a new CMS reimbursement decision and broader U.S. commercial expansion offset a near-term revenue hit from Middle East shipment delays.· November 10, 2026
- Q3 revenue rose 75% year over year to $7.3 million, driven by 15 scanner sales versus 9 a year ago.
- Gross profit was $3 million and gross margin was 41.3%, roughly flat sequentially at 41.2%.
- CMS established separate Medicare hospital outpatient payment for diagnostic QT scan examinations effective January 1, 2027, removing a major reimbursement uncertainty.
- The company expanded its U.S. sales structure and said the Premier national agreement now gives access to nearly 4,400 hospitals and health systems.
- Full-year 2026 revenue guidance was cut to about $34 million from about $39 million because of shipment delays to Saudi Arabia and the UAE.
Third-quarter 2026 revenue was $7.3 million, up 75% from $4.2 million in the third quarter of 2025. Scanner sales were 15 in the quarter versus 9 a year ago, and first-nine-month revenue was $21.3 million versus $10.7 million last year. Gross profit was $3 million versus $1.8 million a year ago, with gross margin at 41.3% compared with 41.2% in Q2 2026. Operating loss was $2.4 million versus $1.7 million a year ago; net loss was about $297,000, or $0.02 per share, versus $4.6 million, or $0.47 per share, last year, helped by a $2.4 million non-cash gain on the earn-out liability. Net cash used in operating activities was $2.2 million in Q3, and cash, cash equivalents and restricted cash were about $8.4 million at September 30. Management revised full-year 2026 revenue outlook to approximately $34 million from approximately $39 million, citing Middle East shipment delays; U.S. scanner shipment plans were said to be unchanged.
Raluca Dinu framed the quarter as evidence that QT Imaging is moving from product development into broader commercialization, with stronger direct sales execution, a larger qualified pipeline, and new distribution reach through Premier and NXT Imaging/Canon Medical Systems USA. She emphasized the CMS reimbursement win as a major milestone that clears a path for hospital outpatient payment starting in 2027 and said the company’s focus now is converting access and reimbursement into installations and clinical adoption. Her tone was upbeat but disciplined, repeatedly stressing execution, evidence generation, and financial discipline.
Jay Jennings said third-quarter revenue of $7.3 million was driven primarily by scanner sales, while gross margin held at 41.3% despite higher operating spending. He noted operating expenses rose to $5.5 million as the company added commercial personnel and advanced clinical work, with R&D at $1.7 million and SG&A at $3.8 million. He also highlighted $2.2 million of operating cash outflow in Q3, $10.7 million used in the first nine months, and cash of about $8.4 million at quarter-end. On guidance, he lowered full-year revenue to about $34 million from about $39 million because of Middle East shipment delays, while saying U.S. shipment plans were unchanged.
Analysts focused on the implications of the CMS reimbursement decision, and management said the next step is to make sure hospitals and clinics understand the billing and coding guide while beginning payer discussions for broader coverage. Questions also centered on the Middle East delay; management said delayed scanners will be shipped as soon as conditions allow, but could not commit to timing because shipping routes remain uncertain. On cash, management said it is not planning to raise money right now and will wait to close Q4 before deciding whether additional capital is needed. Analysts also asked about the U.S. sales buildout, and management said the current senior sales team is covering East and West Coast territories and will be evaluated over the first two quarters of 2027 before any further hiring.
The call gave QT Imaging two important growth catalysts: a clearer Medicare payment pathway for diagnostic use and a larger U.S. hospital channel through Premier. Management also said the U.S. commercial pipeline is expanding, scanner manufacturing capacity roughly doubled after the Petaluma move, and Q4 gross margin should improve because GCC scanners carry higher pricing. The company also said it has already imaged about 13,000 women and is building the clinical evidence base for broader adoption.
The biggest near-term risk is that Middle East logistics disruptions are delaying shipments and forced a reduction in full-year revenue guidance by about $5 million. The company is still in early stages commercially, with reimbursement limited to diagnostic use rather than screening, and management said broader payer coverage still requires additional evidence. Cash remains limited at about $8.4 million, and management did not commit to raising capital only said it would reassess after Q4.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 55.6%
- Shares Outstanding
- 14.69M
- Float Shares
- 8.17M
of shares held by institutions
30 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Lynrock Lake LP | 1.11M | 0 |
| Alyeska Investment Group, L.P. | 702.78K | 0 |
| Sio Capital Management, LLC | 440.45K | ▲ 425.21K |
| Vanguard Capital Management LLC | 356.45K | 0 |
| Bleichroeder LP | 316.67K | 0 |
| Geode Capital Management, LLC | 135.42K | 0 |
| Stonepine Capital Management, LLC | 100.00K | 0 |
| Perkins Capital Management Inc | 100.00K | 0 |
| Polar Asset Management Partners Inc. | 92.52K | ▲ 40.84K |
| Vanguard Fiduciary Trust Co | 70.00K | ▲ 19.23K |
| Blackrock, Inc. | 65.19K | ▲ 3.83K |
| Millennium Management LLC | 46.02K | ▼ 9.31K |
Held by 25 ETFs
Biggest fund positions in QTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 28, 26 | Dinu Raluca | other | 484,221 |
| Jul 28, 26 | Taylor Ross | other | 0 |
| Aug 4, 26 | TIMM BRYAN | other | 9,000 |
| Jul 28, 26 | TIMM BRYAN | other | 0 |
| Mar 20, 26 | Taylor Ross | other | 3,500 |
| Mar 20, 26 | Weiner Zeev | other | 3,500 |
| Mar 17, 26 | Weiner Zeev | other | 14,166 |
| Mar 17, 26 | Weiner Zeev | other | 8,888 |
| Mar 17, 26 | Weiner Zeev | other | 8,888 |
| Mar 17, 26 | Weiner Zeev | other | 14,166 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our QTI coverage
Recent articles, reports, and earnings notes.
No research on QTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate QTI report →QT Imaging to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
businesswire.com · Nov 17
QT Imaging Holdings, Inc. (QTI) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
QT Imaging Reports 75% Third Quarter Revenue Growth and Major Medicare Reimbursement Milestone
businesswire.com · Nov 10
QT Imaging Secures First GCC Commercial Order from American Hospital Dubai, Plans Clinical Research Collaboration
businesswire.com · Nov 10
QT Imaging Secures Medicare Outpatient Reimbursement for QTscan®, Effective January 2027
businesswire.com · Nov 9
QT Imaging to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
businesswire.com · Nov 5
QT Imaging to Report Third Quarter 2026 Financial Results and Host Conference Call on November 10, 2026
businesswire.com · Nov 2
QT Imaging's Breast Acoustic CT™ Scanner Now Available Through National Group Purchasing Agreement with Premier
gurufocus.com · Oct 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.